year 18, Issue 72 And S12 (Supplement 12 2019)                   J. Med. Plants 2019, 18(72 And S12): 299-307 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Amini N, Rezaei K, Bahrami M, Yazdannik A. Effect of Nebulized Eucalyptus on Ventilator Associated Pneumonia in Ventilated Patients. J. Med. Plants 2019; 18 (72) :299-307
1- Instructor, School of Paramedical Sciences, Arak University of Medical Sciences, Arak, Iran
2- Department of Nursing, School of Nursing and Midwifery, Arak University of Medical Sciences, Arak, Iran Instructor
3- B.Sc of Anesthesia, Arak University of Medical Sciences, Arak, Iran
4- Department of Critical Care Nursing, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran ,
Abstract:   (3423 Views)
Background: Ventilator associated pneumonia (VAP) is a common nosocomial infection among patients admitted in ICUs. It results in prolonged intensive care unit (ICU) stay, excess healthcare costs, and higher mortality.
Objective: This study aims to assess the effect of nebulized eucalyptus (NE) on ventilator associated pneumonia in ventilated patients.
Method: We performed a randomized clinical trial study in three intensive care units of educational hospital. Seventy intubated patients that likely required mechanical ventilation for more than 72 hours were selected through purposive sampling and randomly divided into NE (n = 35) and Placebo (n = 35) groups. NE group received 4 ml (5%) eucalyptus in 6 ml normal saline (NS) every 8 h. Placebo group received only 10 ml NS in the same way. At the fifth, ninth day and before extubation VAP was diagnosed through modified clinical pulmonary infection score (MCPIS).
Results: VAP was found in 11 (31.4%) patients receiving NE and in 23 (65.7%) patients in the control group (P = 0.004). The median of duration of intubation in study population was 9.4 ± 3.75 (3-14 day) (P = 0.13). Patients with pneumonia had longer intubation than non-infected patients
(P = 0.001).
Conclusion: NE can reduce ventilator associated pneumonia in ventilated patients.
Full-Text [PDF 469 kb]   (1018 Downloads)    
Type of Study: Research | Subject: Pharmacology & Toxicology
Received: 2018/08/10 | Accepted: 2019/01/20 | Published: 2020/03/7

1. Zampieri FG, Nassar Jr AP, Gusmao-Flores D, Taniguchi LU, Torres A and Ranzani OT. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Critical Care. 2015; 19 (1): 150. [DOI:10.1186/s13054-015-0868-y]
2. Othman HA, Gamil NM, Elgazzar AEM and Fouad TA. Ventilator associated pneumonia, incidence and risk factors in emergency intensive care unit Zagazig university hospitals. Egyptian Journal of Chest Diseases and Tuberculosis 2017; 66 (4): 703 - 8. [DOI:10.1016/j.ejcdt.2017.08.004]
3. Khalifehzadeh A, Parizade A, Hosseini A and Yousefi H. The effects of an oral care practice on incidence of pneumonia among ventilator patients in ICUs of selected hospitals in Isfahan, 2010. Iranian J. Nursing and Midwifery Res. 2012; 17 (3): 216.
4. Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA and et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Critical Care Medicine 2014; 42 (3): 601 - 9. [DOI:10.1097/01.ccm.0000435665.07446.50]
5. Charles MP, Kali A, Easow JM, Joseph NM, Ravishankar M, Srinivasan S and et al. Ventilator-associated pneumonia. The Australasian Medical J. 2014; 7 (8): 334. [DOI:10.4066/AMJ.2014.2105]
6. Ranjan N, Chaudhary U, Chaudhry D and Ranjan K. Ventilator-associated pneumonia in a tertiary care intensive care unit: Analysis of incidence, risk factors and mortality. Indian J. Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine 2014; 18 (4): 200. [DOI:10.4103/0972-5229.130570]
7. Kalanuria AA, Zai W and Mirski M. Ventilator-associated pneumonia in the ICU. Critical Care. 2014; 18 (2): 208. [DOI:10.1186/cc13775]
8. Dosher WB, Loomis EC, Richardson SL, Crowell JA, Waltman RD, Miller LD, etal. The effect of a nurse-led multidisciplinary team on ventilator-associated pneumonia rates. Critical Care Research and Practice 2014; 2014: 682621. [DOI:10.1155/2014/682621]
9. Michalopoulos A and Falagas M. Inhaled antibiotics in mechanically ventilated patients. Minerva Anestesiol. 2014; 80 (2): 236 - 44.
10. Amini N, Rezaei K and Yazdannik A. Effect of nebulized eucalyptus on contamination of microbial plaque of endotracheal tube in ventilated patients. IJNMR. 2016; 21 (2): 165. [DOI:10.4103/1735-9066.178242]
11. Kollef M and Micek S. Recommendations for aerosolized antibiotics in ventilator-associated pneumonia and ventilator-associated tracheobronchitis: too little and too late? Clinical Microbiology and Infection 2017; 23 (9): 593 - 5. [DOI:10.1016/j.cmi.2017.04.001]
12. Solé-Lleonart C, Roberts JA, Chastre J, Poulakou G, Palmer LB, Blot S and et al. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clinical Microbiology and Infection 2016; 22 (4): 359 - 64. [DOI:10.1016/j.cmi.2015.12.016]
13. Khodish FAA, Mohammed M, ABD E-AM and Ibrahem H. Knowledge and performance of critical care nurses toward nebulizer therapy in the intensive care unit at Assiut University Hospital. Med. J. Cairo Univ. 2013; 81 (2): 81 - 94.
14. Bassetti M, Luyt C-E, Nicolau DP and Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Annals of Intensive Care 2016; 6 (1): 35. [DOI:10.1186/s13613-016-0140-x]
15. Horváth G and Ács K. Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti‐inflammatory action: a review. Flavour and Fragrance J. 2015; 30 (5): 331 - 41. [DOI:10.1002/ffj.3252]
16. Sadlon AE and Lamson DW. Immune-modifying and antimicrobial effects of Eucalyptus oil and simple inhalation devices. Alternative Medicine Rev. 2010; 15 (1): 33-47.
17. Gruenwald J, Brendler T and Jaenicke C. PDR for herbal medicines. Thomson, Reuters; 2007.
18. Safdar N, O'Horo JC, Mak R and Medow J. Agreement between the clinical pulmonary infection score and NHSN criteria for surveillance of ventilator associated pneumonia. International Journal of Infection Control 2013; 9 (1): i1. [DOI:10.3396/ijic.v9i1.008.13]
19. Oliva Corujo L, Pérez Pérez A, Guzmán Pérez N and Peña Oliva S. Profilaxis de la neumonía asociada a ventilación con aerosoles de eucalipto. Medisan 2008; 12 (1):1-4.
20. Vimalanathan S, Hudson J. Anti-influenza virus activity of essential oils and vapors. American Journal of Essential Oils and Natural Products 2014; 2 (1): 47 - 53.
21. Elaissi A, Rouis Z, Salem NAB, Mabrouk S, ben Salem Y, Salah KBH and et al. Chemical composition of 8 eucalyptus species' essential oils and the evaluation of their antibacterial, antifungal and antiviral activities. BMC Complementary and Alternative Medicine 2012; 12 (1): 81. [DOI:10.1186/1472-6882-12-81]
22. Sadlon AE and Lamson DW. Immune-modifying and antimicrobial effects of Eucalyptus oil and simple inhalation devices. Alternative Medicine Review. 2010; 15 (1): 33-47.
23. Abu-Salah T and Dhand R. Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update. Advances in Therapy 2011; 28 (9): 728. [DOI:10.1007/s12325-011-0051-z]
24. Hassan NA, Awdallah FF, Abbassi MM and Sabry NA. Nebulized versus IV amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: A randomized controlled trial. Critical Care Medicine 2018; 46 (1): 45 - 52. [DOI:10.1097/CCM.0000000000002695]
25. Póvoa FCC, Cardinal-Fernandez P, Maia IS, Reboredo MM and Pinheiro BV. Effect of antibiotics administered via the respiratory tract in the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. J. Critical Care 2018; 43: 240 - 5. [DOI:10.1016/j.jcrc.2017.09.019]
26. Migiyama Y, Hirosako S, Tokunaga K, Migiyama E, Tashiro T, Sagishima K and et al. Aerosolized tobramycin for Pseudomonas aeruginosa ventilator-associated pneumonia in patients with acute respiratory distress syndrome. Pulmonary Pharmacology & Therapeutics 2017; 45: 142 - 7. [DOI:10.1016/j.pupt.2017.04.008]
27. Palmer LB. Ventilator-associated infection: the role for inhaled antibiotics. Current Opinion in Pulmonary Medicine 2015; 21 (3): 239 - 49. [DOI:10.1097/MCP.0000000000000160]
28. Gupta S, Boville BM, Blanton R, Lukasiewicz G, Wincek J, Bai C and et al. A multicentered prospective analysis of diagnosis, risk factors, and outcomes associated with pediatric ventilator-associated pneumonia. Pediatric Critical Care Medicine 2015; 16 (3): e65 - 73. [DOI:10.1097/PCC.0000000000000338]
29. Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA and et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Critical Care Medicine 2014; 42 (3): 601 - 9. [DOI:10.1097/01.ccm.0000435665.07446.50]
30. Foglia E, Meier MD and Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clinical Microbiol. Reviews 2007; 20 (3): 409 - 25. [DOI:10.1128/CMR.00041-06]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb